Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response.

The Arcus anti-TIGIT molecule is also differentiated from Roche’s tiragolumab given use of Fc-inactive domain for its anti-TIGIT antibody which could enable better safety and tolerability, the ...

Roche announced that the Skyscraper-01 trial studying TIGIT antibody tiragolumab in combination with Roche's approved oncology drug Tecentriq in patients with PD-L1 positive non-small cell lung ...

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S. agency has invalidated a Seagen patent. LegoChem has sold a large ...

SAN FRANCISCO -- Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with ...

Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn't improve overall response rate in the phase II ...

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an immune checkpoint protein that has gained attention as a potential therapeutic target. Both antagonists and agonists have been developed ...

iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Read more on ITOS stock here.

From Roche Holding AG to Novartis AG, bad news abounds for anti-TIGIT immunotherapies. In an SEC filing on July 11, Chinese oncology R&D firm Beigene Ltd. and Basel, Switzerland-based Novartis ...